Jeffrey Weber

Jeffrey Weber is a principal architect of modern melanoma immunotherapy trials and a foremost authority on checkpoint inhibitor immune-related adverse event management. He conducted pivotal trials establishing nivolumab activity in ipilimumab-refractory melanoma and contributed to establishing adjuvant nivolumab as standard of care after resection of stage III/IV melanoma in the CheckMate 238 trial. His research characterized the spectrum of immune-related adverse events of checkpoint inhibitors and developed evidence-based management algorithms for steroid therapy and immunosuppression. His work on biomarkers predicting immunotherapy response and toxicity has advanced personalized immunotherapy approaches in melanoma.